プロテインAレジンの世界市場 - ソース・成分マトリクス・用途・利用者別分析と産業の規模、シェアおよび成長予測：2030年まで
Protein A Resin Market Research Report: By Source, Matrix, Application, End User and Industry Size, Share, Trends and Forecast to 2030
|発行||Prescient & Strategic Intelligence Private Limited||商品コード||930704|
|出版日||ページ情報||英文 184 Pages
|プロテインAレジンの世界市場 - ソース・成分マトリクス・用途・利用者別分析と産業の規模、シェアおよび成長予測：2030年まで Protein A Resin Market Research Report: By Source, Matrix, Application, End User and Industry Size, Share, Trends and Forecast to 2030|
|出版日: 2020年01月01日||ページ情報: 英文 184 Pages||
The major protein A resin market drivers are the increasing geriatric population, prevalence of chronic diseases, funding for protein research, and need to meet the need for therapies for various conditions. The market revenue is projected to surge to $1,020.7 million by 2030, from $486.4 million in 2019, at a 7.0% CAGR during the forecast period (2019-2030). Protein A resin is used as a separation medium during purification processes, such immunoprecipitation and chromatography. It separates biochemical mixtures based on the enzyme-substrate, antigen-antibody, and receptor-nucleic acid interactions.
Based on source, the protein A resin market is bifurcated into natural and recombinant, of which the recombinant bifurcation would display the higher CAGR, of 7.5%, during the forecast period. This is because recombinant protein A resins are heavily used during the production of monoclonal antibodies (mAb). Earlier, pharmaceutical companies did not pursue mAbs, owing to their stability, size, degradation rate, and delivery limitations. But, with increasing funding and focus of private and public institutions on protein-based research, the development of mAbs is picking up pace.
Across the world, the need for effective treatments for metabolic diseases, cardiovascular diseases, infectious diseases, and cancer is highly unmet. This is promoting the development of monoclonal antibodies, as they can function similar to the mediators involved in pathological processes. Additionally, mAbs and other therapeutic proteins are less toxic, highly effective and potent, safe, tolerable, selective, and chemically and biologically diverse, and they also do not accumulate much on tissues. Therefore, with the increase in the research and development (R&D) for mAbs, the usage of protein A resin would rise.
The application segment of the market also has two bifurcations - antibody purification and immunoprecipitation - of which antibody purification held the larger share in 2019 and it would also grow faster during the forecast period, at a 7.2% CAGR. Similarly, of the two bifurcations within the end user segment - academic institutes & research laboratories and biotechnology & pharmaceutical industries - the latter dominated the protein A resin market in 2019, with a 91.6% value share. This end user consumes the biomaterial in huge amounts to produce mAbs.
One of the primary reasons behind the rising demand for monoclonal antibodies is the increasing incidence of chronic diseases. mAbs display a suitable pharmacokinetic profile, their solubility can be customized, and they also have a lesser chance of inducing an immune response, which is essential for the treatment to work. The diseases caused by hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human papillomavirus (HPV) are increasing in prevalence, due to the low accessibility of healthcare in developing nations.
As per the Joint United Nations Program on HIV and AIDS (UNAIDS), 36.9 million had HIV in 2017. Similarly, as per the data jointly published by the American Stroke Association (ASA) and American Heart Association (AHA), heart diseases killed 836,546 people in the U.S. in 2018. Further, the World Health Organization (WHO) estimates the number of cancer cases, expected to be diagnosed in 2030, at 21.4 million. Thus, the rising prevalence of such diseases will lead to a surging demand for mAbs, thereby driving the protein A resin market advance.
Geographically, North America led the market in 2019, with a share of 37.4%, owing to the increasing requirement for protein therapeutics for chronic diseases and rising number of biopharmaceuticals with the Food and Drug Administration's approval. During the forecast period, Asia-Pacific (APAC) would observe the fastest progress in the protein A resin market during the forecast period, at a 7.8% CAGR. This would be because of the rising usage of such biomaterial in drug research, technological advancements, growing pharmaceutical sector, and surging demand for vaccines and other therapeutics.
Therefore, with the increasing R&D for drugs and disease treatment, especially for monoclonal antibodies, the consumption of protein A resin would also escalate.